Kestra Medical Technologies, Ltd. (KMTS) Reports Q3 Loss of $0.50, provides guidance

Kestra Medical Technologies, Ltd. (NASDAQ: KMTS) reported Q3 EPS of ($0.50). Revenue for the quarter came in at $19.4 million.

Fiscal Year 2026 Revenue Guidance
Kestra is increasing its FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25. This compares to prior FY26 revenue guidance of $85 million.

For earnings history and earnings-related data on Kestra Medical Technologies, Ltd. (KMTS) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• INVO Fertility (IVF) Tops Q2 EPS by 105c
• Iran to escalate tensions in region if diplomacy with U.S. fails - Reuters